Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company’s lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications. NOX-A12 is designed to enhance the effectiveness of anti-cancer treatments, including immuno-oncology approaches such as immune checkpoint inhibitors and current standards of care such as chemotherapy and radiotherapy, without adding significant new side effects for patients. Mangasarian told Scrip the ideal partner for Noxxon currently would be one that could offer a potential cancer drug for combination with its pipeline therapeutics, as well as financial backing.
Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Aram Mangasarian – CEO, Noxxon